Abstract
Background/Objectives: Evidence suggests that modifiable lifestyle interventions improve disability in relapsing multiple sclerosis (MS); however, interactions between different factors may impact outcomes. Thus, the objective of this secondary analysis was to investigate diet-induced effects on the impact of MS and effect modification by other modifiable lifestyle factors. Methods: The physical and psychological impact of MS was assessed with the MS Impact Scale-29 (MSIS) at run-in, baseline, 12 weeks, and 24 weeks. Participants were randomized at baseline to the Swank low-saturated fat or Wahls modified Paleolithic elimination diets and instructed to maintain usual physical activity, objectively measured with an accelerometer, throughout the trial. Baseline information on sleep, physical activity, alcohol, and smoking was explored as effect modifiers. Results: Among the Swank group, MSIS-Physical scores improved from 33.8 ± 3.8 at baseline to 28.7 ± 3.6 at 12 weeks (p = 0.04) and 25.3 ± 3.5 at 24 weeks (p < 0.001). MSIS-Psychological scores also improved from 35.7 ± 3.3 at baseline to 25.6 ± 2.6 at 12 weeks (p = 0.001) and 22.8 ± 2.4 at 24 weeks (p < 0.001). Among the Wahls group, MSIS-Physical scores improved from 33.8 ± 3.1 at baseline to 21.7 ± 3.0 at 12 weeks (p < 0.001) and 19.0 ± 3.1 at 24 weeks (p < 0.001). MSIS-Psychological scores also improved from 38.4 ± 3.8 at baseline to 25.5 ± 3.8 at 12 weeks (p < 0.001) and 20.6 ± 3.6 at 24 weeks (p < 0.001). Improvements in MSIS-Physical were greater among participants who were physically inactive or drank little alcohol at baseline. Conclusions: Both diets led to favorable within-group improvements in the perceived impact of MS. People with MS who are physically inactive or drink little alcohol may benefit the most from dietary interventions.
1. Introduction
Multiple sclerosis (MS) is a chronic immune-mediated disorder characterized by central nervous system demyelination that affects around 2.8 million individuals worldwide [1]. Modifiable lifestyle behaviors are an area with high interest among people with MS [2]. Individually, many modifiable lifestyle factors are linked to better MS outcomes including diet [3,4], exercise [5,6], smoking session [7], and sleep quality [8], among others. In addition, one prospective observational study observed that engagement in multiple modifiable lifestyle behaviors was positively associated with quality of life over time [9] and several multimodal intervention studies have shown benefit of a variety of combinations of modifiable lifestyle behaviors [10,11,12,13]. However, evidence on interactions between modifiable lifestyle behaviors and MS outcomes remains sparse. One small single-arm safety and feasibility trial investigating the impact of a multimodal lifestyle intervention observed that adherence to the study diet (modified Paleolithic) was associated with 12-month improvements in fatigue, mood, and cognitive function, whereas adherence to the exercise, neuromuscular electrical stimulation, massage, and meditation components were not associated with 12-month changes in outcomes [14]. Other multimodal lifestyle intervention studies have not reported on the relationships between individual intervention factors and outcomes in MS.
Our research group previously conducted the WAVES randomized parallel-arm trial, comparing the effects of the Swank low-saturated fat diet and the Wahls modified Paleolithic elimination diets on fatigue among people with relapsing MS [15]. This study showed that both diets lead to reductions in fatigue and improvements in mental and physical quality of life [16] as the primary outcomes, as well as cognitive function [17], mental health [18], and cardiometabolic health [19] as secondary analyses. Furthermore, an additional secondary analysis of the WAVES trial found that both diet groups had significant within-group improvements in functional disability as assessed with the MS Functional Composite [20], a finding that has since been replicated in a secondary analysis of a pilot randomized controlled trial among people with relapsing MS [21]. While encouraging, these findings necessitate further research, particularly to explore how interactions between modifiable lifestyle factors affect the perceived impact of MS. Improved understanding in this area could inform future lifestyle interventions targeted to people with MS.
Rich data were also collected in the WAVES trial on physical activity, sleep, and other modifiable lifestyle behaviors as well as the physical and psychological impacts of MS as assessed by the MS Impact Scale (MSIS) [15], which has yet to be reported. Therefore, WAVES trial data present an opportunity to explore the interactions with other modifiable lifestyle behaviors of diet-induced effects on MS impact among people with relapsing MS. Thus, the objective of this secondary analysis was to investigate diet-induced effects on the impact of MS and effect modification by other modifiable lifestyle factors including sleep, physical activity, alcohol consumption, and smoking status.
2. Materials and Methods
2.1. Participants
This is a secondary analysis of secondary outcomes from a 36-week, randomized, parallel-arm, single-blinded trial conducted at the University of Iowa Prevention Intervention Center [15]. The study was approved by the University of Iowa and the VAMC Institutional Review Boards and followed the updated Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines [22]. Written informed consent was obtained from all participants prior to enrollment. A National Multiple Sclerosis Society (NMSS) data safety monitoring board monitored the trial for data safety management. All participants provided written and informed consent and were recruited from within 500 miles of Iowa City, IA [15]. Individuals, ages 18–70, were determined to be eligible if they had the following: (1) relapsing MS confirmed by a neurologist based on the 2010 McDonald criteria [23], (2) moderate to severe fatigue, (3) the ability to walk 25 feet with unilateral or no support, (4) not pregnant or planning to become pregnant for 12 months at recruitment, and (5) willingness to comply with all study interventions and assessments. Participants were excluded if they had the following: (1) MS relapse, change in disease-modifying drug use, and/or change in medications for symptom management within 12 weeks prior to recruitment; (2) low BMI (<19 kg/m2) and/or a diagnosed eating disorder; (3) severe cognitive impairment defined by the Short Portable Mental Status Questionnaire [24]; (4) self-reported adverse reactions to gluten-containing foods or a diagnosis of celiac disease; (5) diagnosis of severe psychiatric disorders, kidney stones, heart failure, angina, or liver cirrhosis; and treatment with insulin, warfarin, radiation, or chemotherapy. A comprehensive list of eligibility criteria may be found in the protocol [15].
2.2. Study Design
Data were collected at four time points spaced 12 weeks apart each: run-in, baseline, 12 weeks, and 24 weeks. The run-in visit was for observation purposes and participants were randomized 1:1 at baseline to either the low-saturated fat (Swank) or the modified Paleolithic elimination (Wahls) diet interventions for 24 weeks. Diet education and support were provided by Registered Dietitian Nutritionists (RDNs) for the first 12 weeks of intervention. For the second 12 weeks of intervention, scheduled RDN support was discontinued, but participants could contact the RDNs at any time for assistance. Every four weeks, RDNs emailed feedback to participants regarding their dietary checklists to encourage maintained adherence to their assigned study diets.
2.3. Study Diets
The Swank diet restricts saturated fat intake to <15 g/day and allows 20–50 g of unsaturated fat, four servings of grains (whole preferred), and four servings of fruits and vegetables per day. The Wahls diet emphasizes fruit and vegetable intake, allowing 6–9 servings/day, in addition to 6–12 ounces/day of meat with variations based on sex. This diet excludes grains, legumes, eggs, and dairy, except for clarified butter and ghee. Nightshade vegetables and seed spices were also excluded for the first 12 weeks of the intervention and were re-introduced by participants if desired and under RDN supervision to safely test tolerance. All participants were instructed to follow a daily supplement regimen including cod liver oil, methyl-B12, methyl-folate, a multi-vitamin without iron, and vitamin D3 adjusted based on serum levels [15]. Participants were instructed to maintain their usual physical activity level throughout the course of the study [15]. For each group, dietary adherence was high, previously reported as 87% among the Swank group and 80% among the Wahls group at 12 weeks, which is the primary endpoint [16].
2.4. Outcomes
The MSIS questionnaire was utilized to assess the perceived physical and psychological impact of MS. This validated 29-item questionnaire comprises two subscales, the physical impact subscale (MSIS -Physical, 20 items) and the psychological impact subscale (MSIS-Psychological, nine items) [25]. Items were scored on five-point scales, with higher numbers corresponding to greater burden of MS for each item. For both MSIS outcomes, a positive or negative change of 7.5 points was considered clinically significant [26,27].
2.5. Effect Modifiers
The Pittsburgh Sleep Quality Index (PSQI) was used to quantify perceived sleep quality [28]. This 19-item self-report questionnaire is a valid and reliable measure of perceived sleep quality in MS [29]. Values < 5 were considered good sleep quality and values ≥ 5 were considered poor sleep quality [28].
The International Physical Activity Questionnaire (IPAQ) Long was used to assess self-reported physical activity across several domains of daily living, including household activity, transportation, and leisure-time exercise [30]. Time spent in varying intensities of physical activity (light, moderate, and vigorous) were calculated based on standard scoring procedures [31]. The IPAQ has also been shown to be valid among people with MS with mild disability [32].
Participants also wore an accelerometer (GT9X Link; ActiGraph®, Pensacola, FL, USA) on their non-dominant wrist, 24 h per day during a 7-day recording period immediately prior to each study visit. In addition to daily steps, time spent engaged in light-, moderate-, and vigorous-intensity physical activity, sedentary behavior, and sleep behavior were calculated using the Hildebrand equations [33,34]. Participants were considered physically active if they did 150 min of moderate intensity activity, or 75 min of vigorous-intensity activity [35].
Smoking status and alcohol consumption were self-reported in baseline health questionnaires.
2.6. Statistical Analysis
Descriptive statistics were calculated for every variable at enrollment using frequencies (%), means ± standard errors, and medians (interquartile ranges). Distributions of continuous variables were evaluated for normality by graphical observation, and outliers were checked for accuracy.
Generalized linear mixed models (GLMMs) [36] were used to estimate and test the interacting effects of diet and time on outcome measures while accounting for repeated measures for each participant using a random effect. Missing data were included and accounted for in the GLMMs. Models for outcomes with normal and right-skewed distributions specified identity and log link functions, respectively. Other potentially important variables (age, sex, BMI, walking assistance, years since MS diagnosis, disease-modifying drug use, baseline vitamin D, baseline 6-min walk test distance, and educational attainment) were considered for inclusion in each model to assess their relationship with the outcome and obtain the modified estimates for the diet and time effects. For each unique model (outcome and predictor set combination), the Akaike information criterion (AIC) [37] was calculated for model selection. For each outcome, the model with the smallest AIC was deemed the optimal predictor set for estimating each adjusted relationship. Point estimates, 95% CIs, and p-values of the group-specific mean changes in outcome measures over visits were generated for each optimal model.
Moderating effects of lifestyle factors on physical and psychological impacts of MS were assessed using least-square means in linear mixed models, that included the relevant baseline categorical lifestyle factor as a fixed effect. All moderation analyses included diet assignment as a covariate in models.
All analyses were conducted with two-sided tests (α = 0.05) using SAS software (version 9.4, SAS Institute, Inc., Cary, NC, USA).
3. Results
This secondary analysis included 77 participants (38 Swank and 39 Wahls) who completed the study primary endpoint through 12 weeks (Figure S1). At baseline, there were no significant differences in mean values associated with physical, behavioral, or demographic parameters between the two diet groups (Table 1). Throughout the trial, there were no significant changes in levels of physical activity (both self-reported and objectively measured) or sleep duration in either diet group (Table S1).
Table 1.
Baseline characteristics of participants who completed a 12-week intervention of the Swank or Wahls diets a.
There were no differences between diet groups at any time point for MSIS-Physical or MSIS-Psychological. However, significant within-group reductions in MSIS-Physical and MSIS-Psychological scores were observed in both groups at 12 weeks (Table 2). At 24 weeks, scores decreased further from its level at 12 weeks. For the Swank group, mean MSIS-Physical scores decreased from 33.8 ± 3.8 at baseline to 28.7 ± 3.6 at 12 weeks (p = 0.04) and to 25.3 ± 3.5 at 24 weeks (p < 0.001). In addition, mean MSIS-Psychological scores decreased from 35.7 ± 3.3 at baseline to 25.6 ± 3.0 at 12 weeks (p < 0.001) and 22.8 ± 2.4 at 24 weeks (p < 0.001). For the Wahls group, mean MSIS-Physical score decreased from 33.8 ± 3.1 at baseline to 21.7 ± 3.0 (p < 0.001) at 12 weeks and 19.0 ± 3.1 (p < 0.001) at 24 weeks. In addition, mean MSIS-Psychological score decreased from 38.4 ± 3.8 at baseline to 25.5 ± 3.8 at 12 weeks (p < 0.001) and 20.6 ± 3.6 at 24 weeks (p < 0.001). Both diet groups experienced high frequencies of individuals with clinically significant improvements in both MSIS outcomes at 12 and 24 weeks (range 38.5% to 65.8%) and relatively low frequencies of individuals with clinically significant worsening (range 0% to 13.9%; Table S2).
Table 2.
MS impact and sleep quality among participants with relapsing MS assigned to the Swank or Wahls dietary interventions a.
Both groups also experienced significant improvements in mean PSQI scores after 12 weeks, with further reductions in each score at 24 weeks (Table 2). For the Swank diet, mean PSQI score decreased from 6.89 ± 0.52 at baseline to 5.92 ± 0.55 at 12 weeks (p = 0.003) and to 5.43 ± 0.56 at 24 weeks (p < 0.001). For the Wahls diet, mean PSQI score decreased from 6.95 ± 0.51 at baseline to 6.08 ± 0.49 at 12 weeks (p = 0.03) and to 5.23 ± 0.58 at 24 weeks (p < 0.001).
At baseline, participants with good sleep quality had lower MSIS-Psychological scores (p = 0.004) and participants who were physically active (both self-reported and objectively measured) had lower MSIS-Physical scores (p = 0.003 and 0.002, respectively; Table 3). Furthermore, baseline levels of objectively measured physical activity and alcohol status moderated decreases in MSIS-Physical scores at 24 weeks. MSIS-Physical scores among participants who were inactive at baseline decreased by −18.0 ± 2.79 compared to a decrease of 8.98 ± 1.84 among participants who were active (p = 0.009). Similarly, MSIS-Physical scores among participants who consumed ≤1 drink/day at baseline decreased by −15.3 ± 2.32 compared to a decrease of −8.13 ± 2.14 among participants who consumed >1 drink/day at baseline (p = 0.03). No other significant moderating effects were observed.
Table 3.
Moderation effects of baseline lifestyle factors on diet-induced changes in MS impact a,b.
4. Discussion
Both the Swank and Wahls dietary interventions led to within-group reductions in the physical and psychological impact of MS at 12 and 24 weeks compared to baseline values. Additionally, both diet groups experienced within-group improvements in sleep quality. Furthermore, baseline levels of physical activity and alcohol consumption moderated reductions in the physical impact of MS at 24 weeks such that participants who were objectively physically inactive or drank ≤1 alcohol-containing drink per day had the greatest diet-induced reductions in MSIS-Physical values.
Participants with poor sleep quality had higher psychological impact of MS at baseline. Poor sleep quality is associated with fatigue and disability burden among people with MS [38], suggesting that interventions that improve sleep quality and fatigue may reduce disability burden. Notably, another previous secondary analysis of the WAVES trial observed that both the Swank and Wahls diets led to reductions in functional disability objectively assessed by the MS Functional Composite, as mediated by reductions in fatigue [20].
A second key finding of this secondary analysis was the observation that individuals who did less objectively measured physical activity at baseline had larger reductions in physical MS impact at 24 weeks. This observation may be attributable to individuals who were not physically active prior to the study having a larger margin for improvement with the adoption of a dietary intervention and is supported by the observation that physically active participants had significantly lower physical MS impact at baseline. A similar observation that dietary interventions may improve physical functioning more among people with lower physical activity was noted among nearly 50,000 postmenopausal women in the Women’s Health Initiative Dietary Modification Trial [39]. Therefore, dietary changes may be an especially promising option for individuals who have less ability to do physical activity, to reduce the negative physical impacts of MS.
Furthermore, participants who self-reported drinking >1 alcoholic beverage/day at baseline had smaller reductions in physical impacts of MS at 24 weeks. The association of alcohol consumption with less favorable outcomes may be attributable to alcohol’s known neurodegenerative effects in MS [40]. Furthermore, high alcohol intake is associated with higher rates of anxiety and depression among people with MS, ref. [41] both of which are associated with perceived MS disability [42] and were previously shown to improve in the WAVES trial [18]. Alternatively, low-to-moderate levels of alcohol consumption is associated with reduced physical disability and improved quality of life among people with MS [43,44]. These observations in conjunction with the present findings suggest that efforts to reduce alcohol intake to low/moderate levels may be a key component of dietary/lifestyle interventions among people with MS and high consumption.
The strengths of this study include the consistency of run-in and baseline values, use of blinded assessors and statisticians, use of objective measures with complimentary patient-reported outcomes for sleep and physical activity, high adherence to the dietary interventions [16], no change in physical activity (assessed via Actigraph® and total IPAQ) further demonstrating intervention adherence, and repeated measures of outcomes. This study was limited by the lack of a control group. Additionally, this study included many exclusion criteria and lacked diversity as it included primarily individuals who were white and/or female. The interventions were only 24 weeks in duration, limiting the knowledge gained for long-term outcomes. In addition, objectively measured sleep quality was not assessed. Furthermore, the effects of nightshade vegetable re-introduction for Wahls participants from 12 to 24 weeks were not independently studied.
Lifestyle modifications may be an important way for people with MS to reduce the physical and psychological impacts of MS. Inclusion of lifestyle modifications in MS care may allow for personalized care plans to meet patient goals. Sleep quality may be an important interlinking therapeutic target, as it is shown to mediate diet-induced improvements in the physical and psychological impacts of MS. Physical activity and alcohol consumption are important considerations when examining the potential efficacy of dietary interventions. Assessing baseline behaviors may help identify patients with MS who may benefit the most from implementing dietary changes. Future trials are needed to investigate the synergistic effects of lifestyle modifications on symptoms of MS and MS progression.
Supplementary Materials
The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/sclerosis4010007/s1; Table S1: Self-reported and objectively measured physical activity of participants with relapsing MS during dietary intervention trial; Table S2: Frequency (%) with clinically significant changes in MS impact. Figure S1: Study recruitment and participant flow diagram.
Author Contributions
Conceptualization, T.J.T., L.G.S. and T.L.W.; methodology, L.G.S. and T.L.W.; formal analysis, T.J.T. and P.T.E.; data curation, T.J.T. and P.T.E.; writing—original draft preparation, L.R.B. and T.J.T.; writing—review and editing, F.S., P.T.E., K.F.H., L.J.C., W.G.D., L.G.S. and T.L.W.; visualization, T.J.T.; supervision, P.T.E., K.F.H., L.J.C., W.G.D., L.G.S. and T.L.W.; project administration, T.J.T.; funding acquisition, L.G.S. and T.L.W. All authors have read and agreed to the published version of the manuscript.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The parent trial was supported in part by the National Multiple Sclerosis Society grant RG-1506-04312 (TLW), University of Iowa institutional funds, and the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UM1TR004403. FS is a research trainee of the University of Iowa Fraternal Order of Eagles Diabetes Research Center (T32DK112751-08). TJT and FS were additionally supported by the Carter Chapman Shreve Family Foundation and the Carter Chapman Shreve Fellowship Fund for diet and lifestyle research conducted by the Wahls Research team at the University of Iowa. In-kind support was provided by the University of Iowa College of Public Health Preventive Intervention Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or National MS Society. The study sponsors had no role in the conduct, analysis, or decision to publish this research.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Boards of the University of Iowa (IRB identifier 201604705, approved on 21 June 2016.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data presented in this study are available upon reasonable request from the corresponding author. The data are not publicly available due to the privacy of the study participants.
Acknowledgments
The authors would like to acknowledge Mary Ehlinger for her role in study recruitment and as the primary study coordinator; Karen Smith for her role in nutrition data acquisition and as an intervention dietitian; Lisa Brooks for her role as an intervention dietitian; Michaella Edwards for her role in study coordination and data acquisition; Zaidoon Al-Share for his role in data acquisition; and the students who supported recruitment and data acquisition. The authors also thank Kristina Greiner for her editing assistance.
Conflicts of Interest
TLW personally follows and promotes the Wahls™ diet. She has equity interest in the following companies: Dr. Terry Wahls LLC; TZ Press LLC; The Wahls Institute, PLC; FBB Biomed Inc; Foogal Inc.; Levels Health Inc.; Well Theory Inc., and the website http://www.terrywahls.com. She also owns the copyright to the books Minding My Mitochondria (2nd Edition), The Wahls Protocol, and The Wahls Protocol Cooking for Life, as well as the trademarks The Wahls Protocol ® and Wahls™, Wahls Paleo™, Wahls Paleo Plus™ diets and Wahls Behavior Change™. She has completed grant funding from the National Multiple Sclerosis Society for the Dietary Approaches to Treating Multiple Sclerosis-Related Fatigue Study. She has financial relationships with MasterHealth Technologies Inc. and the Institute for Functional Medicine. She receives royalty payments from Penguin Random House. TLW has conflict of interest management plans in place with the University of Iowa and the Iowa City Veteran’s Affairs Medical Center. No other authors declare conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
- Walton, C.; King, R.; Rechtman, L.; Kaye, W.; Leray, E.; Marrie, R.A.; Robertson, N.; La Rocca, N.; Uitdehaag, B.; van der Mei, I.; et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. 2020, 26, 1816–1821. [Google Scholar] [CrossRef] [Scilit]
- Dunn, M.; Bhargava, P.; Kalb, R. Your Patients with Multiple Sclerosis have Set Wellness as a High Priority—And the National Multiple Sclerosis Society is Responding. US Neurol. 2015, 11, 80–86. [Google Scholar] [CrossRef] [Scilit]
- Solsona, E.M.; Tektonidis, T.; Reece, J.C.; Simpson-Yap, S.; Black, L.J.; Rad, E.Y.; Coe, S. Associations between diet and disease progression and symptomatology in multiple sclerosis: A systematic review of observational studies. Mult. Scler. Relat. Disord. 2024, 87, 105636. [Google Scholar] [CrossRef] [Scilit]
- Snetselaar, L.G.; Cheek, J.J.; Fox, S.S.; Healy, H.S.; Schweizer, M.L.; Bao, W.; Kamholz, J.; Titcomb, T.J. Efficacy of Diet on Fatigue and Quality of Life in Multiple Sclerosis: A Systematic Review and Network Meta-analysis of Randomized Trials. Neurology 2023, 100, e357–e366. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Du, L.; Xi, H.; Zhang, S.; Zhou, Y.; Tao, X.; Lv, Y.; Hou, X.; Yu, L. Effects of exercise in people with multiple sclerosis: A systematic review and meta-analysis. Front. Public. Health 2024, 12, 1387658. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Flores, V.A.; Silic, P.; DuBose, N.G.; Zheng, P.; Jeng, B.; Motl, R.W. Effects of aerobic, resistance, and combined exercise training on health-related quality of life in multiple sclerosis: Systematic review and meta-analysis. Mult. Scler. Relat. Disord. 2023, 75, 104746. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rodgers, J.; Friede, T.; Vonberg, F.W.; Constantinescu, C.S.; Coles, A.; Chataway, J.; Duddy, M.; Emsley, H.; Ford, H.; Fisniku, L.; et al. The impact of smoking cessation on multiple sclerosis disease progression. Brain 2022, 145, 1368–1378. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Laslett, L.L.; Honan, C.; Turner, J.A.; Dagnew, B.; Campbell, J.A.; Gill, T.K.; Appleton, S.; Blizzard, L.; Taylor, B.V.; van der Mei, I. Poor sleep and multiple sclerosis: Associations with symptoms of multiple sclerosis and quality of life. J. Neurol. Neurosurg. Psychiatry 2022, 93, 1162–1165. [Google Scholar] [CrossRef] [Scilit]
- Fidao, A.; Jelinek, G.; Simpson-Yap, S.; Neate, S.; Nag, N. Engagement with three or more healthy lifestyle behaviours is associated with improved quality of life over 7.5 years in people with multiple sclerosis. Eur. J. Neurol. 2023, 30, 3190–3199. [Google Scholar] [CrossRef] [Scilit]
- Bevens, W.; Weiland, T.J.; Gray, K.; Neate, S.L.; Nag, N.; Simpson-Yap, S.; Reece, J.; Yu, M.; Jelinek, G.A. The Feasibility of a Web-Based Educational Lifestyle Program for People with Multiple Sclerosis: A Randomized Controlled Trial. Front. Public Health 2022, 10, 852214. [Google Scholar] [CrossRef] [Scilit]
- Nauta, I.M.; Loughlin, K.N.M.; Gravesteijn, A.S.; van Wegen, J.; Hofman, R.P.; Wilmsen, N.; Coles, E.; van Kempen, Z.L.E.; Killestein, J.; van Oosten, B.W.; et al. A multi-domain lifestyle intervention in multiple sclerosis: A longitudinal observational study. J. Neurol. 2025, 272, 476. [Google Scholar] [CrossRef] [Scilit]
- Ng, A.; Kennedy, P.; Hutchinson, B.; Ingram, A.; Vondrell, S.; Goodman, T.; Miller, D. Self-efficacy and health status improve after a wellness program in persons with multiple sclerosis. Disabil. Rehabil. 2013, 35, 1039–1044. [Google Scholar] [CrossRef] [Scilit]
- Titcomb, T.J.; Sherwood, M.; Ehlinger, M.; Saxby, S.M.; Shemirani, F.; Eyck, P.T.; Wahls, T.L.; Snetselaar, L.G. Evaluation of a web-based program for the adoption of wellness behaviors to self-manage fatigue and improve quality of life among people with multiple sclerosis: A randomized waitlist-control trial. Mult. Scler. Relat. Disord. 2023, 77, 104858. [Google Scholar] [CrossRef] [Scilit]
- Bisht, B.; Darling, W.G.; Shivapour, E.T.; Lutgendorf, S.K.; Snetselaar, L.G.; Chenard, C.A.; Wahls, T.L. Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: A pilot study. Degener. Neurol. Neuromuscul. Dis. 2015, 5, 19–35. [Google Scholar] [CrossRef] [Scilit]
- Wahls, T.; Scott, M.O.; Alshare, Z.; Rubenstein, L.; Darling, W.; Carr, L.; Smith, K.; Chenard, C.A.; LaRocca, N.; Snetselaar, L. Dietary approaches to treat MS-related fatigue: Comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: Study protocol for a randomized controlled trial. Trials 2018, 19, 309. [Google Scholar] [CrossRef] [Scilit]
- Wahls, T.L.; Titcomb, T.J.; Bisht, B.; Eyck, P.T.; Rubenstein, L.M.; Carr, L.J.; Darling, W.G.; Hoth, K.F.; Kamholz, J.; Snetselaar, L.G. Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: The WAVES randomized parallel-arm clinical trial. Mult. Scler. J. Exp. Transl. Clin. 2021, 7, 20552173211035399. [Google Scholar] [CrossRef] [Scilit]
- Saxby, S.M.; Haas, C.; Shemirani, F.; Titcomb, T.J.; Eyck, P.T.; Rubenstein, L.M.; Hoth, K.F.; Snetselaar, L.G.; Wahls, T.L. Association Between Improved Serum Fatty Acid Profiles and Cognitive Function During a Dietary Intervention Trial in Relapsing-Remitting Multiple Sclerosis. Int. J. MS Care 2024, 26, 61–68. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Shemirani, F.; Titcomb, T.J.; Saxby, S.M.; Eyck, P.T.; Rubenstein, L.M.; Hoth, K.F.; Snetselaar, L.G.; Wahls, T.L. Association of serum homocysteine, folate, and vitamin B(12) and mood following the Swank and Wahls elimination dietary interventions in relapsing-remitting multiple sclerosis: Secondary analysis of the WAVES trial. Mult. Scler. Relat. Disord. 2023, 75, 104743. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Villa, A.T.; Tu, B.H.; Titcomb, T.J.; Saxby, S.M.; Shemirani, F.; Ten Eyck, P.; Rubenstein, L.M.; Snetselaar, L.G.; Wahls, T.L. Association between improved metabolic risk factors and perceived fatigue during dietary intervention trial in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES trial. Front. Neurol. 2022, 13, 1022728. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Crippes, L.J.; Saxby, S.M.; Shemirani, F.; Bisht, B.; Gill, C.; Rubenstein, L.M.; Ten Eyck, P.; Carr, L.J.; Darling, W.G.; Hoth, K.F.; et al. Diet-induced changes in functional disability are mediated by fatigue in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES randomized parallel-arm trial. Mult. Scler. J. Exp. Transl. Clin. 2023, 9, 20552173231209147. [Google Scholar] [CrossRef] [Scilit]
- Groux, A.R.; Walker, E.S.; Shemirani, F.; Lee, J.E.; Irish, A.K.; Rubenstein, L.M.; Snetselaar, L.G.; Darling, W.G.; Wahls, T.L.; Titcomb, T.J. Diet-Induced Changes in Functional Disability among People with Multiple Sclerosis: A Secondary Pooled Analysis of Two Randomized Controlled Pilot Trials. Sclerosis 2024, 2, 156–165. [Google Scholar] [CrossRef] [Scilit]
- Hopewell, S.; Chan, A.W.; Collins, G.S.; Hrobjartsson, A.; Moher, D.; Schulz, K.F.; Tunn, R.; Aggarwal, R.; Berkwits, M.; Berlin, J.A.; et al. CONSORT 2025 statement: Updated guideline for reporting randomised trials. BMJ 2025, 389, e081123. [Google Scholar] [CrossRef] [Scilit]
- Polman, C.H.; Reingold, S.C.; Banwell, B.; Clanet, M.; Cohen, J.A.; Filippi, M.; Fujihara, K.; Havrdova, E.; Hutchinson, M.; Kappos, L.; et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69, 292–302. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Pfeiffer, E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J. Am. Geriatr. Soc. 1975, 23, 433–441. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hobart, J.; Lamping, D.; Fitzpatrick, R.; Riazi, A.; Thompson, A. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain 2001, 124, 962–973. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Greene, N.; Quere, S.; Bury, D.P.; Mazerolle, F.; M’Hari, M.; Loubert, A.; Regnault, A.; Higuchi, K. Establishing clinically meaningful within-individual improvement thresholds for eight patient-reported outcome measures in people with relapsing-remitting multiple sclerosis. J. Patient Rep. Outcomes 2023, 7, 61. [Google Scholar] [CrossRef] [Scilit]
- Phillips, G.A.; Wyrwich, K.W.; Guo, S.; Medori, R.; Altincatal, A.; Wagner, L.; Elkins, J. Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening. Mult. Scler. 2014, 20, 1753–1760. [Google Scholar] [CrossRef] [Scilit]
- Buysse, D.J.; Reynolds, C.F., 3rd; Monk, T.H.; Berman, S.R.; Kupfer, D.J. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28, 193–213. [Google Scholar] [CrossRef] [Scilit]
- Jerkovic, A.; Mikac, U.; Matijaca, M.; Kosta, V.; Curkovic Katic, A.; Dolic, K.; Vujovic, I.; Soda, J.; Dogas, Z.; Pavelin, S.; et al. Psychometric Properties of the Pittsburgh Sleep Quality Index (PSQI) in Patients with Multiple Sclerosis: Factor Structure, Reliability, Correlates, and Discrimination. J. Clin. Med. 2022, 11, 2037. [Google Scholar] [CrossRef] [Scilit]
- Craig, C.L.; Marshall, A.L.; Sjostrom, M.; Bauman, A.E.; Booth, M.L.; Ainsworth, B.E.; Pratt, M.; Ekelund, U.; Yngve, A.; Sallis, J.F.; et al. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. Sports Exerc. 2003, 35, 1381–1395. [Google Scholar] [CrossRef] [Scilit]
- IPAQ Executive Committee. Guidelines for the Data Processing and Analysis of the International Physical Activity Questionnaire. Available online: https://www.researchgate.net/file.PostFileLoader.html?id=56f92d66615e27d49a658031&assetKey=AS%3A344600888791041%401459170662924 (accessed on 1 October 2024).
- Wanitschek, A.; Seebacher, B.; Muehlbacher, A.; Brenneis, C.; Ehling, R. Comparison of patient-reported outcomes of physical activity and accelerometry in people with multiple sclerosis and ambulatory impairment: A cross-sectional study. Mult. Scler. Relat. Disord. 2024, 85, 105532. [Google Scholar] [CrossRef] [Scilit]
- Hildebrand, M.; VT, V.A.N.H.; Hansen, B.H.; Ekelund, U. Age group comparability of raw accelerometer output from wrist- and hip-worn monitors. Med. Sci. Sports Exerc. 2014, 46, 1816–1824. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hildebrand, M.; Hansen, B.H.; van Hees, V.T.; Ekelund, U. Evaluation of raw acceleration sedentary thresholds in children and adults. Scand. J. Med. Sci. Sports 2017, 27, 1814–1823. [Google Scholar] [CrossRef] [Scilit]
- U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd ed.; U.S. Department of Health and Human Services: Washington, DC, USA, 2018. [Google Scholar]
- Mcculloch, C.E.; Neuhaus, J.M. Generalized Linear Mixed Models. In Wiley StatsRef: Statistics Reference Online; Balakrishnan, N., Colton, T., Everitt, B., Piegorsch, W., Ruggeri, F., Teugels, J.L., Eds.; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2014. [Google Scholar]
- Akaike, H. A new look at the statistical model identification. IEEE Trans. Autom. Control. 1974, 19, 716–723. [Google Scholar] [CrossRef] [Scilit]
- Bhattarai, J.J.; Patel, K.S.; Dunn, K.M.; Brown, A.; Opelt, B.; Hughes, A.J. Sleep disturbance and fatigue in multiple sclerosis: A systematic review and meta-analysis. Mult. Scler. J. Exp. Transl. Clin. 2023, 9, 20552173231194352. [Google Scholar] [CrossRef] [Scilit]
- Chlebowski, R.T.; Aragaki, A.K.; Pan, K.; Nelson, R.A.; Barac, A.; Manson, J.E.; Stefanick, M.L.; Ikramuddin, F.S.; Johnson, K.C.; Krok-Schoen, J.L.; et al. Dietary Intervention Favorably Influences Physical Functioning: The Women’s Health Initiative Randomized Dietary Modification Trial. J. Acad. Nutr. Diet. 2024, 124, 1409–1418 e1406. [Google Scholar] [CrossRef] [Scilit]
- Kleerekooper, I.; Chua, S.; Foster, P.J.; Trip, S.A.; Plant, G.T.; Petzold, A.; Patel, P.; Eye, U.K.B.; Vision, C. Associations of Alcohol Consumption and Smoking with Disease Risk and Neurodegeneration in Individuals with Multiple Sclerosis in the United Kingdom. JAMA Netw. Open 2022, 5, e220902. [Google Scholar] [CrossRef] [Scilit]
- Quesnel, S.; Feinstein, A. Multiple sclerosis and alcohol: A study of problem drinking. Mult. Scler. 2004, 10, 197–201. [Google Scholar] [CrossRef] [Scilit]
- Curatoli, C.; Marcassoli, A.; Barbadoro, F.; Fornari, A.; Leonardi, M.; Raggi, A.; Schiavolin, S.; Terragni, R.; Antozzi, C.; Brambilla, L.; et al. Anxiety, Depression, and Expanded Disability Status Scale Independently Predict the Perception of Disability in Persons with Multiple Sclerosis: A Cross-Sectional Study. Behav. Neurol. 2025, 2744955. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Wu, J.; Olsson, T.; Hillert, J.A.; Alfredsson, L.; Hedstrom, A.K. Association Between Alcohol Consumption and Disability Accumulation in Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2024, 11, e200289. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Weiland, T.J.; Hadgkiss, E.J.; Jelinek, G.A.; Pereira, N.G.; Marck, C.H.; van der Meer, D.M. The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis. J. Neurol. Sci. 2014, 336, 211–219. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.